Knight Therapeutics Seeks Expanded Use of MINJUVI in Brazil for First-Line Lymphoma Treatment
Event summary
- Knight Therapeutics submitted a supplemental regulatory application to ANVISA for MINJUVI (tafasitamab) as a first-line treatment for DLBCL and HGBL in Brazil.
- The submission is based on Phase 3 frontMIND trial results and is part of Project Orbis for expedited review.
- MINJUVI is already approved in Brazil for relapsed or refractory DLBCL and follicular lymphoma.
- Knight holds exclusive distribution rights for MINJUVI in Latin America under an agreement with Incyte.
The big picture
Knight's submission represents a strategic push to expand MINJUVI's use in earlier-stage lymphoma treatment, addressing a significant unmet need in Brazil. The move aligns with broader industry trends of targeting aggressive lymphomas with combination therapies. Success could position Knight as a key player in Latin America's oncology market, though it faces competition from established treatments and regulatory hurdles.
What we're watching
- Regulatory Success
- Whether ANVISA's review under Project Orbis will lead to expedited approval for MINJUVI's new indication.
- Market Expansion
- The pace at which Knight can secure similar approvals in other Latin American markets.
- Commercial Execution
- How Knight will position MINJUVI against existing first-line therapies in Brazil.